Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Soignet, SL; Frankel, SR; Douer, D; Tallman, MS; Kantarjian, H; Calleja, E; Stone, RM; Kalaycio, M; Scheinberg, DA; Steinherz, P; Sievers, EL; Coutre, S; Dahlberg, S; Ellison, R; Warrell, RP
   United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
   JOURNAL OF CLINICAL ONCOLOGY
   
   S.L. Soignet et al., "United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia", J CL ONCOL, 19(18), 2001, pp. 3852-3860
2. He, LZ; Tolentino, T; Grayson, P; Zhong, S; Warrell, RP; Rifkind, RA; Marks, PA; Richon, VM; Pandolfi, PP
   Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
   JOURNAL OF CLINICAL INVESTIGATION
   
   L.Z. He et al., "Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia", J CLIN INV, 108(9), 2001, pp. 1321-1330
3. Jurcic, JG; Nimer, SD; Scheinberg, DA; DeBlasio, T; Warrell, RP; Miller, WH
   Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
   BLOOD
   
   J.G. Jurcic et al., "Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia", BLOOD, 98(9), 2001, pp. 2651-2656
4. Soignet, SL; Miller, VA; Pfister, DG; Bienvenu, BJ; Ho, R; Parker, BA; Amyotte, SA; Cato, A; Warrell, RP
   Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)
   CLINICAL CANCER RESEARCH
   
   S.L. Soignet et al., "Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)", CLIN CANC R, 6(5), 2000, pp. 1731-1735
5. Camacho, LH; Soignet, SL; Chanel, S; Ho, R; Heller, G; Scheinberg, DA; Ellison, R; Warrell, RP
   Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
   JOURNAL OF CLINICAL ONCOLOGY
   
   L.H. Camacho et al., "Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide", J CL ONCOL, 18(13), 2000, pp. 2620-2625
6. Brooks, AD; Tong, W; Benedetti, F; Kaneda, Y; Miller, V; Warrell, RP
   Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery
   CANCER CHEMOTHERAPY AND PHARMACOLOGY
   
   A.D. Brooks et al., "Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery", CANC CHEMOT, 46(4), 2000, pp. 313-318
7. Novick, SC; Warrell, RP
   Arsenicals in hematologic cancers
   SEMINARS IN ONCOLOGY
   
   S.C. Novick e R.P. Warrell, "Arsenicals in hematologic cancers", SEMIN ONCOL, 27(5), 2000, pp. 495-501
8. Rego, EM; He, LZ; Warrell, RP; Wang, ZG; Pandolfi, PP
   Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RAR alpha and PLZF-RAR alpha oncoproteins
   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
   
   E.M. Rego et al., "Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RAR alpha and PLZF-RAR alpha oncoproteins", P NAS US, 97(18), 2000, pp. 10173-10178
9. Roboz, GJ; Dias, S; Lam, G; Lane, WJ; Soignet, SL; Warrell, RP; Rafii, S
   Arsenic trioxide induces dose- and time-dependent apoptosis of endotheliumand may exert an antileukemic effect via inhibition of angiogenesis
   BLOOD
   
   G.J. Roboz et al., "Arsenic trioxide induces dose- and time-dependent apoptosis of endotheliumand may exert an antileukemic effect via inhibition of angiogenesis", BLOOD, 96(4), 2000, pp. 1525-1530
10. Warrell, RP
    Gallium nitrate and bone metastases
    TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS
    
    R.P. Warrell, "Gallium nitrate and bone metastases", TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 483-492
11. Soignet, SL; Tong, WP; Hirschfeld, S; Warrell, RP
    Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    S.L. Soignet et al., "Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia", CANC CHEMOT, 44(5), 1999, pp. 417-421
12. Warrell, RP; Pandolfi, PP
    Treatment of acute promyelocytic leukemia with arsenic trioxide - Reply
    NEW ENGLAND JOURNAL OF MEDICINE
    
    R.P. Warrell e P.P. Pandolfi, "Treatment of acute promyelocytic leukemia with arsenic trioxide - Reply", N ENG J MED, 340(13), 1999, pp. 1044-1045
13. Warrell, RP
    Re: Therapeutic targeting of transcription in acute promyelocytic leukemiaby use of an inhibitor of histone deacetylase - Reply
    JOURNAL OF THE NATIONAL CANCER INSTITUTE
    
    R.P. Warrell, "Re: Therapeutic targeting of transcription in acute promyelocytic leukemiaby use of an inhibitor of histone deacetylase - Reply", J NAT CANC, 91(5), 1999, pp. 476-476
14. SOIGNET SL; MASLAK P; CHEN YW; CALLEJA E; PANDOLFI PP; SCHEINBERG DA; WARRELL RP
    WESTERN STUDY OF ARSENIC TRIOXIDE (AS2O3) IN PATIENTS WITH RELAPSED AND OR REFRACTORY ACUTE PROMYELOCYTIC LEUKEMIA/
    Annals of oncology
    
    S.L. Soignet et al., "WESTERN STUDY OF ARSENIC TRIOXIDE (AS2O3) IN PATIENTS WITH RELAPSED AND OR REFRACTORY ACUTE PROMYELOCYTIC LEUKEMIA/", Annals of oncology, 9, 1998, pp. 675-675
15. SOIGNET SL; BENEDETTI F; FLEISCHAUER A; PARKER BA; TRUGLIA JA; CRISP MR; WARRELL RP
    CLINICAL-STUDY OF 9-CIS RETINOIC ACID (LGD1057) IN ACUTE PROMYELOCYTIC LEUKEMIA
    Leukemia
    
    S.L. Soignet et al., "CLINICAL-STUDY OF 9-CIS RETINOIC ACID (LGD1057) IN ACUTE PROMYELOCYTIC LEUKEMIA", Leukemia, 12(10), 1998, pp. 1518-1521
16. SOIGNET SL; MASLAK P; WANG ZG; JHANWAR S; CALLEJA E; DARDASHTI LJ; CORSO D; DEBLASIO A; GABRILOVE J; SCHEINBERG DA; PANDOLFI PP; WARRELL RP
    COMPLETE REMISSION AFTER TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ARSENIC TRIOXIDE
    The New England journal of medicine
    
    S.L. Soignet et al., "COMPLETE REMISSION AFTER TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ARSENIC TRIOXIDE", The New England journal of medicine, 339(19), 1998, pp. 1341-1348
17. SOIGNET SL; MASLAK P; CHEN YW; CALLEJA E; PANDOLFI PP; SCHEINBERG DA; WARRELL RP
    COMPLETE REMISSION AFTER CLINICALLY INDUCED-DIFFERENTIATION AND APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA BY ARSENIC TRIOXIDE
    British Journal of Haematology
    
    S.L. Soignet et al., "COMPLETE REMISSION AFTER CLINICALLY INDUCED-DIFFERENTIATION AND APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA BY ARSENIC TRIOXIDE", British Journal of Haematology, 102(1), 1998, pp. 225-225
18. WANG ZG; RIVI R; DELVA L; KONIG A; SCHEINBERG DA; GAMBACORTIPASSERINI C; GABRILOVE JL; WARRELL RP; PANDOLFI PP
    ARSENIC TRIOXIDE AND MELARSOPROL INDUCE PROGRAMMED CELL-DEATH IN MYELOID-LEUKEMIA CELL-LINES AND FUNCTION IN A PML AND PML-RAR-ALPHA INDEPENDENT MANNER
    Blood
    
    Z.G. Wang et al., "ARSENIC TRIOXIDE AND MELARSOPROL INDUCE PROGRAMMED CELL-DEATH IN MYELOID-LEUKEMIA CELL-LINES AND FUNCTION IN A PML AND PML-RAR-ALPHA INDEPENDENT MANNER", Blood, 92(5), 1998, pp. 1497-1504
19. WARRELL RP; HE LZ; RICHON V; CALLEJA E; PANDOLFI PP
    THERAPEUTIC TARGETING OF TRANSCRIPTION IN ACUTE PROMYELOCYTIC LEUKEMIA BY USE OF AN INHIBITOR OF HISTONE DEACETYLASE
    Journal of the National Cancer Institute
    
    R.P. Warrell et al., "THERAPEUTIC TARGETING OF TRANSCRIPTION IN ACUTE PROMYELOCYTIC LEUKEMIA BY USE OF AN INHIBITOR OF HISTONE DEACETYLASE", Journal of the National Cancer Institute, 90(21), 1998, pp. 1621-1625
20. NIESVIZKY R; WARRELL RP
    PATHOPHYSIOLOGY AND MANAGEMENT OF BONE-DISEASE IN MULTIPLE-MYELOMA
    Cancer investigation
    
    R. Niesvizky e R.P. Warrell, "PATHOPHYSIOLOGY AND MANAGEMENT OF BONE-DISEASE IN MULTIPLE-MYELOMA", Cancer investigation, 15(1), 1997, pp. 85-90
21. MILLER VA; BENEDETTI FM; RIGAS JR; VERRET AL; PFISTER DG; STRAUS D; KRIS MG; CRISP M; HEYMAN R; LOEWEN GR; TRUGLIA JA; WARRELL RP
    INITIAL CLINICAL-TRIAL OF A SELECTIVE RETINOID-X RECEPTOR-LIGAND, LGD1069
    Journal of clinical oncology
    
    V.A. Miller et al., "INITIAL CLINICAL-TRIAL OF A SELECTIVE RETINOID-X RECEPTOR-LIGAND, LGD1069", Journal of clinical oncology, 15(2), 1997, pp. 790-795
22. SOIGNET S; FLEISCHAUER A; POLYAK T; HELLER G; WARRELL RP
    ALL-TRANS-RETINOIC ACID SIGNIFICANTLY INCREASES 5-YEAR SURVIVAL IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA - LONG-TERM FOLLOW-UP OF THE NEW-YORK STUDY
    Cancer chemotherapy and pharmacology
    
    S. Soignet et al., "ALL-TRANS-RETINOIC ACID SIGNIFICANTLY INCREASES 5-YEAR SURVIVAL IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA - LONG-TERM FOLLOW-UP OF THE NEW-YORK STUDY", Cancer chemotherapy and pharmacology, 40, 1997, pp. 25-29
23. WARRELL RP
    CLINICAL AND MOLECULAR ASPECTS OF RETINOID THERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA
    International journal of cancer
    
    R.P. Warrell, "CLINICAL AND MOLECULAR ASPECTS OF RETINOID THERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA", International journal of cancer, 70(4), 1997, pp. 496-497
24. WARRELL RP
    GALLIUM NITRATE FOR THE TREATMENT OF BONE METASTASES
    Cancer
    
    R.P. Warrell, "GALLIUM NITRATE FOR THE TREATMENT OF BONE METASTASES", Cancer, 80(8), 1997, pp. 1680-1685
25. KONIG A; WRAZEL L; WARRELL RP; RIVI R; PANDOLFI PP; JAKUBOWSKI A; GABRILOVE JL
    COMPARATIVE ACTIVITY OF MELARSOPROL AND ARSENIC TRIOXIDE IN CHRONIC B-CELL LEUKEMIA LINES
    Blood
    
    A. Konig et al., "COMPARATIVE ACTIVITY OF MELARSOPROL AND ARSENIC TRIOXIDE IN CHRONIC B-CELL LEUKEMIA LINES", Blood, 90(2), 1997, pp. 562-570
26. HE LZ; PERUZZI D; TRIBIOLI C; WARRELL RP; PANDOLFI PP
    THERAPEUTIC TRIALS WITH RETINOIC ACID AND ARSENIC TRIOXIDE (ASO3) IN PML-RAR-ALPHA AND PLZF-RAR-ALPHA TRANSGENIC MICE AS MODELS OF APL
    Blood
    
    L.Z. He et al., "THERAPEUTIC TRIALS WITH RETINOIC ACID AND ARSENIC TRIOXIDE (ASO3) IN PML-RAR-ALPHA AND PLZF-RAR-ALPHA TRANSGENIC MICE AS MODELS OF APL", Blood, 90(10), 1997, pp. 825-825
27. WANG ZG; RIVI R; DELVA L; KONIG A; SOIGNET S; SCHEINBERG D; GAMBACORTIPASSERINI C; GABRILOVE JL; WARRELL RP; PANDOLFI PP
    ARSENIC TRIOXIDE AND MELARSOPROL INDUCE PROGRAMMED CELL-DEATH IN MYELOID-LEUKEMIA CELL-LINES AND FUNCTION IN A PML AND PML RAR-ALPHA INDEPENDENT MANNER/
    Blood
    
    Z.G. Wang et al., "ARSENIC TRIOXIDE AND MELARSOPROL INDUCE PROGRAMMED CELL-DEATH IN MYELOID-LEUKEMIA CELL-LINES AND FUNCTION IN A PML AND PML RAR-ALPHA INDEPENDENT MANNER/", Blood, 90(10), 1997, pp. 1461-1461
28. JURCIC JG; DEBLASIO A; DUMONT L; WARRELL RP; SCHEINBERG DA
    MOLECULAR REMISSION INDUCTION WITHOUT RELAPSE AFTER ANTI-CD33 MONOCLONAL-ANTIBODY HUM195 IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)
    Blood
    
    J.G. Jurcic et al., "MOLECULAR REMISSION INDUCTION WITHOUT RELAPSE AFTER ANTI-CD33 MONOCLONAL-ANTIBODY HUM195 IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)", Blood, 90(10), 1997, pp. 1850-1850
29. SOIGNET SL; RIVI R; KONIG A; TONG WP; GABRILOVE J; SCHEINBERG DA; PANDOLFI PP; WARRELL RP
    MELARSOPROL, AN ORGANIC ARSENICAL, IN THE TREATMENT OF REFRACTORY LEUKEMIA - LABORATORY AND CLINICAL-RESULTS
    Blood
    
    S.L. Soignet et al., "MELARSOPROL, AN ORGANIC ARSENICAL, IN THE TREATMENT OF REFRACTORY LEUKEMIA - LABORATORY AND CLINICAL-RESULTS", Blood, 90(10), 1997, pp. 2258-2258
30. MILLER VA; RIGAS JR; BENEDETTI FM; VERRET AL; TONG WP; KRIS MG; GILL GM; LOEWEN GR; TRUGLIA JA; ULM EH; WARRELL RP
    INITIAL CLINICAL-TRIAL OF THE RETINOID RECEPTOR PAN AGONIST 9-CIS RETINOIC ACID
    Clinical cancer research
    
    V.A. Miller et al., "INITIAL CLINICAL-TRIAL OF THE RETINOID RECEPTOR PAN AGONIST 9-CIS RETINOIC ACID", Clinical cancer research, 2(3), 1996, pp. 471-475
31. FLOMBAUM CD; ISAACS M; REICH L; BERMAN E; WARRELL RP
    ACUTE-RENAL-FAILURE ASSOCIATED WITH THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA
    American journal of kidney diseases
    
    C.D. Flombaum et al., "ACUTE-RENAL-FAILURE ASSOCIATED WITH THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA", American journal of kidney diseases, 27(1), 1996, pp. 134-137
32. WARRELL RP
    PATHOGENESIS IS AND MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA
    Annual review of medicine
    
    R.P. Warrell, "PATHOGENESIS IS AND MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA", Annual review of medicine, 47, 1996, pp. 555-565
33. RIGAS JR; MILLER VA; ZHANG ZF; KLIMSTRA DS; TONG WP; KRIS MG; WARRELL RP
    METABOLIC PHENOTYPES OF RETINOIC ACID AND THE RISK OF LUNG-CANCER
    Cancer research
    
    J.R. Rigas et al., "METABOLIC PHENOTYPES OF RETINOIC ACID AND THE RISK OF LUNG-CANCER", Cancer research, 56(12), 1996, pp. 2692-2696
34. RIVI R; CALLEJA E; KONIG A; LAI L; GAMBACORTIPASSERINI C; SCHEINBERG D; GABRILOVE JL; WARRELL RP; PANDOLFI PP
    ORGANIC ARSENICAL MELARSOPROL SHOWS GROWTH SUPPRESSIVE ACTIVITY VIA PROGRAMMED CELL-DEATH ON APL AND OTHER MYELOID AND LYMPHOID LEUKEMIA-DERIVED CELL-LINES
    Blood
    
    R. Rivi et al., "ORGANIC ARSENICAL MELARSOPROL SHOWS GROWTH SUPPRESSIVE ACTIVITY VIA PROGRAMMED CELL-DEATH ON APL AND OTHER MYELOID AND LYMPHOID LEUKEMIA-DERIVED CELL-LINES", Blood, 88(10), 1996, pp. 260-260
35. SOIGNET S; TONG WP; GABRILOVE J; SCHEINBERG DA; PANDOLFI PP; WARRELL RP
    INITIAL CLINICAL-STUDY OF A NOVEL ORGANIC ARSENICAL, MELARSOPROL, IN PATIENTS WITH ADVANCED LEUKEMIA
    Blood
    
    S. Soignet et al., "INITIAL CLINICAL-STUDY OF A NOVEL ORGANIC ARSENICAL, MELARSOPROL, IN PATIENTS WITH ADVANCED LEUKEMIA", Blood, 88(10), 1996, pp. 865-865
36. PERUZZI D; DEBLASIO T; WARRELL RP; PANDOLFI PP
    HIGHLY SENSITIVE RT-PCR ASSAY FOR DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA
    Blood
    
    D. Peruzzi et al., "HIGHLY SENSITIVE RT-PCR ASSAY FOR DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA", Blood, 88(10), 1996, pp. 1452-1452
37. KONIG A; WRAZEL L; WARRELL RP; PANDOLFI PP; RIVI R; ALKATIB A; GABRILOVE JL
    IN-VITRO EFFECTS OF MELARSOPROL AS COMPARED TO ARSENIC TRIOXIDE (AS2O3) IN CHRONIC LYMPHOID MALIGNANCIES
    Blood
    
    A. Konig et al., "IN-VITRO EFFECTS OF MELARSOPROL AS COMPARED TO ARSENIC TRIOXIDE (AS2O3) IN CHRONIC LYMPHOID MALIGNANCIES", Blood, 88(10), 1996, pp. 2352-2352
38. JURCIC JG; MILLER WH; DEBLASIO A; SCHEINBERG DA; WARRELL RP
    PROGNOSTIC-SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTION AND PMLRAR-ALPHA ISOFORM TYPE - LONG-TERM FOLLOW-UP IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)/
    Blood
    
    J.G. Jurcic et al., "PROGNOSTIC-SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTION AND PMLRAR-ALPHA ISOFORM TYPE - LONG-TERM FOLLOW-UP IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)/", Blood, 88(10), 1996, pp. 2529-2529
39. VYAS RC; FRANKEL SR; AGBOR P; MILLER WH; WARRELL RP; HITTELMAN WN
    PROBING THE PATHOBIOLOGY OF RESPONSE TO ALL-TRANS-RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA - PREMATURE CHROMOSOME CONDENSATION FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS
    Blood
    
    R.C. Vyas et al., "PROBING THE PATHOBIOLOGY OF RESPONSE TO ALL-TRANS-RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA - PREMATURE CHROMOSOME CONDENSATION FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS", Blood, 87(1), 1996, pp. 218-226
40. RIGAS JR; FRANCIS PA; MILLER VA; TONG WP; ROISTACHER N; KRIS MG; ORAZEM JP; YOUNG CW; WARRELL RP
    CLINICAL AND PHARMACOLOGY STUDY OF CHLOROQUINOXALINE SULFONAMIDE GIVEN ON A WEEKLY SCHEDULE
    Cancer chemotherapy and pharmacology
    
    J.R. Rigas et al., "CLINICAL AND PHARMACOLOGY STUDY OF CHLOROQUINOXALINE SULFONAMIDE GIVEN ON A WEEKLY SCHEDULE", Cancer chemotherapy and pharmacology, 35(6), 1995, pp. 483-488
41. JURCIC JG; CARON PC; NIKULA TK; PAPADOPOULOS EB; FINN RD; GANSOW OA; MILLER WH; GEERLINGS MW; WARRELL RP; LARSON SM; SCHEINBERG DA
    RADIOLABELED ANTI-CD33 MONOCLONAL-ANTIBODY M195 FOR MYELOID LEUKEMIAS
    Cancer research
    
    J.G. Jurcic et al., "RADIOLABELED ANTI-CD33 MONOCLONAL-ANTIBODY M195 FOR MYELOID LEUKEMIAS", Cancer research, 55(23), 1995, pp. 5908-5910
42. WEISS M; WARRELL RP
    2 CASES OF EXTRAMEDULLARY ACUTE PROMYELOCYTIC LEUKEMIA - REPLY
    Cancer
    
    M. Weiss e R.P. Warrell, "2 CASES OF EXTRAMEDULLARY ACUTE PROMYELOCYTIC LEUKEMIA - REPLY", Cancer, 76(1), 1995, pp. 152-152
43. NIESVIZKY R; SIEGEL DS; BUSQUETS X; NICHOLS G; MUINDI J; WARRELL RP; MICHAELI J
    HYPERCALCEMIA AND INCREASED SERUM INTERLEUKIN-6 LEVELS INDUCED BY ALL-TRANS-RETINOIC ACID IN PATIENTS WITH MULTIPLE-MYELOMA
    British Journal of Haematology
    
    R. Niesvizky et al., "HYPERCALCEMIA AND INCREASED SERUM INTERLEUKIN-6 LEVELS INDUCED BY ALL-TRANS-RETINOIC ACID IN PATIENTS WITH MULTIPLE-MYELOMA", British Journal of Haematology, 89(1), 1995, pp. 217-218
44. DYCK JA; WARRELL RP; EVANS RM; MILLER WH
    RAPID DIAGNOSIS OF ACUTE PROMYELOCYTIC LEUKEMIA BY IMMUNOHISTOCHEMICAL LOCALIZATION OF PML RAR-ALPHA PROTEIN/
    Blood
    
    J.A. Dyck et al., "RAPID DIAGNOSIS OF ACUTE PROMYELOCYTIC LEUKEMIA BY IMMUNOHISTOCHEMICAL LOCALIZATION OF PML RAR-ALPHA PROTEIN/", Blood, 86(3), 1995, pp. 862-867
45. JURCIC JG; CARON PC; DEBLASIO A; DUMONT L; WARRELL RP; SCHEINBERG DA
    TARGETED THERAPY WITH HUMANIZED ANTI-CD33 MONOCLONAL-ANTIBODY (HUM195) REDUCES RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA
    Blood
    
    J.G. Jurcic et al., "TARGETED THERAPY WITH HUMANIZED ANTI-CD33 MONOCLONAL-ANTIBODY (HUM195) REDUCES RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA", Blood, 86(10), 1995, pp. 2057-2057
46. MILLER WH; JAKUBOWSKI A; TONG WP; MILLER VA; RIGAS JR; BENEDETTI F; GILL GM; TRUGLIA JA; ULM E; SHIRLEY M; WARRELL RP
    9-CIS RETINOIC ACID INDUCES COMPLETE REMISSION BUT DOES NOT REVERSE CLINICALLY ACQUIRED RETINOID RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA
    Blood
    
    W.H. Miller et al., "9-CIS RETINOIC ACID INDUCES COMPLETE REMISSION BUT DOES NOT REVERSE CLINICALLY ACQUIRED RETINOID RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA", Blood, 85(11), 1995, pp. 3021-3027
47. WARRELL RP; MASLAK P; EARDLEY A; HELLER G; MILLER WH; FRANKEL SR
    TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ALL-TRANS-RETINOIC ACID - AN UPDATE OF THE NEW-YORK EXPERIENCE
    Leukemia
    
    R.P. Warrell et al., "TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ALL-TRANS-RETINOIC ACID - AN UPDATE OF THE NEW-YORK EXPERIENCE", Leukemia, 8(6), 1994, pp. 929-933
48. EARDLEY AM; HELLER G; WARRELL RP
    MORBIDITY AND COSTS OF REMISSION INDUCTION THERAPY WITH ALL-TRANS-RETINOIC ACID COMPARED WITH STANDARD CHEMOTHERAPY IN ACUTE PROMYELOCYTIC LEUKEMIA
    Leukemia
    
    A.M. Eardley et al., "MORBIDITY AND COSTS OF REMISSION INDUCTION THERAPY WITH ALL-TRANS-RETINOIC ACID COMPARED WITH STANDARD CHEMOTHERAPY IN ACUTE PROMYELOCYTIC LEUKEMIA", Leukemia, 8(6), 1994, pp. 934-939
49. MUINDI JRF; YOUNG CW; WARRELL RP
    CLINICAL-PHARMACOLOGY OF ALL-TRANS-RETINOIC ACID
    Leukemia
    
    J.R.F. Muindi et al., "CLINICAL-PHARMACOLOGY OF ALL-TRANS-RETINOIC ACID", Leukemia, 8(11), 1994, pp. 1807-1812
50. MUINDI JRF; YOUNG CW; WARRELL RP
    CLINICAL-PHARMACOLOGY OF ALL-TRANS-RETINOIC ACID
    Leukemia
    
    J.R.F. Muindi et al., "CLINICAL-PHARMACOLOGY OF ALL-TRANS-RETINOIC ACID", Leukemia, 8, 1994, pp. 16-21
51. WARRELL RP; MASLAK P; EARDLEY A; HELLER G; MILLER WH; FRANKEL SR
    TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ALL-TRANS-RETINOIC ACID - AN UPDATE OF THE NEW-YORK EXPERIENCE
    Leukemia
    
    R.P. Warrell et al., "TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ALL-TRANS-RETINOIC ACID - AN UPDATE OF THE NEW-YORK EXPERIENCE", Leukemia, 8, 1994, pp. 33-37
52. WARRELL RP
    THE STANDARD OF CARE IN ACUTE PROMYELOCYTIC LEUKEMIA
    Leukemia
    
    R.P. Warrell, "THE STANDARD OF CARE IN ACUTE PROMYELOCYTIC LEUKEMIA", Leukemia, 8, 1994, pp. 56-58
53. WONG ET; VAHDAT L; TUNKEL RS; WILE MJ; ROSENBLUM M; WARRELL RP; FOLEY KM
    SEVERE MOTOR WEAKNESS FROM HIGH-DOSE 2-CHLORODEOXYADENOSINE
    Annals of neurology
    
    E.T. Wong et al., "SEVERE MOTOR WEAKNESS FROM HIGH-DOSE 2-CHLORODEOXYADENOSINE", Annals of neurology, 36(2), 1994, pp. 293-293
54. MILLER VA; RIGAS JR; MUINDI JRF; TONG WP; VENKATRAMAN E; KRIS MG; WARRELL RP
    MODULATION OF ALL-TRANS-RETINOIC ACID PHARMACOKINETICS BY LIAROZOLE
    Cancer chemotherapy and pharmacology
    
    V.A. Miller et al., "MODULATION OF ALL-TRANS-RETINOIC ACID PHARMACOKINETICS BY LIAROZOLE", Cancer chemotherapy and pharmacology, 34(6), 1994, pp. 522-526
55. BENEDETTI F; MILLER V; RIGAS J; TONG W; JAKUBOWSKI A; SHIRLEY M; ULM E; TRUGLIA J; GILL G; WARRELL RP
    INITIAL CLINICAL AND PHARMACOLOGICAL EVALUATION OF THE RETINOID RECEPTOR PAN-AGONIST, 9-CIS RETINOIC ACID (LGD-1057)
    Experimental hematology
    
    F. Benedetti et al., "INITIAL CLINICAL AND PHARMACOLOGICAL EVALUATION OF THE RETINOID RECEPTOR PAN-AGONIST, 9-CIS RETINOIC ACID (LGD-1057)", Experimental hematology, 22(8), 1994, pp. 795-795
56. WARRELL RP
    APPLICATIONS FOR RETINOIDS IN CANCER-THERAPY - INTRODUCTION
    Seminars in hematology
    
    R.P. Warrell, "APPLICATIONS FOR RETINOIDS IN CANCER-THERAPY - INTRODUCTION", Seminars in hematology, 31(4), 1994, pp. 1-13
57. WARRELL RP; DEGOS L
    ACUTE PROMYELOCYTIC LEUKEMIA - REPLY
    The New England journal of medicine
    
    R.P. Warrell e L. Degos, "ACUTE PROMYELOCYTIC LEUKEMIA - REPLY", The New England journal of medicine, 330(2), 1994, pp. 141-141
58. MUINDI JF; SCHER HI; RIGAS JR; WARRELL RP; YOUNG CW
    ELEVATED PLASMA-LIPID PEROXIDE CONTENT CORRELATES WITH RAPID PLASMA-CLEARANCE OF ALL-TRANS-RETINOIC ACID IN PATIENTS WITH ADVANCED CANCER
    Cancer research
    
    J.F. Muindi et al., "ELEVATED PLASMA-LIPID PEROXIDE CONTENT CORRELATES WITH RAPID PLASMA-CLEARANCE OF ALL-TRANS-RETINOIC ACID IN PATIENTS WITH ADVANCED CANCER", Cancer research, 54(8), 1994, pp. 2125-2128
59. WEISS MA; WARRELL RP
    2 CASES OF EXTRAMEDULLARY ACUTE PROMYELOCYTIC LEUKEMIA - CYTOGENETICS, MOLECULAR-BIOLOGY, AND PHENOTYPIC AND CLINICAL-STUDIES
    Cancer
    
    M.A. Weiss e R.P. Warrell, "2 CASES OF EXTRAMEDULLARY ACUTE PROMYELOCYTIC LEUKEMIA - CYTOGENETICS, MOLECULAR-BIOLOGY, AND PHENOTYPIC AND CLINICAL-STUDIES", Cancer, 74(7), 1994, pp. 1882-1886
60. VAHDAT L; MASLAK P; MILLER WH; EARDLEY A; HELLER G; SCHEINBERG DA; WARRELL RP
    EARLY MORTALITY AND THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTICLEUKEMIA - IMPACT OF LEUKOCYTOSIS, LOW-DOSE CHEMOTHERAPY, PMN RAR-ALPHA ISOFORM, AND CD13 EXPRESSION IN PATIENTS TREATED WITH ALL-TRANS-RETINOIC ACID/
    Blood
    
    L. Vahdat et al., "EARLY MORTALITY AND THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTICLEUKEMIA - IMPACT OF LEUKOCYTOSIS, LOW-DOSE CHEMOTHERAPY, PMN RAR-ALPHA ISOFORM, AND CD13 EXPRESSION IN PATIENTS TREATED WITH ALL-TRANS-RETINOIC ACID/", Blood, 84(11), 1994, pp. 3843-3849
61. BENEDETTI F; MILLER V; RIGAS J; TONG W; ULM E; TRUGLIA J; GILL G; WARRELL RP
    INITIAL CLINICAL-STUDY OF 9-CIS RETINOIC ACID (LGD-1057), A RETINOID RECEPTOR PAN-AGONIST
    Blood
    
    F. Benedetti et al., "INITIAL CLINICAL-STUDY OF 9-CIS RETINOIC ACID (LGD-1057), A RETINOID RECEPTOR PAN-AGONIST", Blood, 84(10), 1994, pp. 10000312-10000312
62. WARRELL RP; MILLER WH; TONG WP; JAKUBOWSKI A; MILLER V; RIGAS JR; BENEDETTI F; GILL G; TRUGLIA J
    9-CIS RETINOIC (LGD1057) YIELDS SUSTAINED PLASMA DRUG CONCENTRATIONS BUT DOES NOT REVERSE CLINICALLY ACQUIRED RETINOID RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA
    Blood
    
    R.P. Warrell et al., "9-CIS RETINOIC (LGD1057) YIELDS SUSTAINED PLASMA DRUG CONCENTRATIONS BUT DOES NOT REVERSE CLINICALLY ACQUIRED RETINOID RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA", Blood, 84(10), 1994, pp. 10000379-10000379
63. MILLER WH; HELLER G; WARRELL RP
    IMPLICATIONS OF THE PML RAR-ALPHA-ISOFORM AT PRESENTATION AND DETECTION OF PML/RAR-ALPHA BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION(RT-PCR) IN REMISSION OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)/
    Blood
    
    W.H. Miller et al., "IMPLICATIONS OF THE PML RAR-ALPHA-ISOFORM AT PRESENTATION AND DETECTION OF PML/RAR-ALPHA BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION(RT-PCR) IN REMISSION OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)/", Blood, 84(10), 1994, pp. 10000379-10000379
64. VAHDAT L; WONG ET; WILE MJ; ROSENBLUM M; FOLEY KM; WARRELL RP
    THERAPEUTIC AND NEUROTOXIC EFFECTS OF 2-CHLORODEOXYADENOSINE IN ADULTS WITH ACUTE MYELOID-LEUKEMIA
    Blood
    
    L. Vahdat et al., "THERAPEUTIC AND NEUROTOXIC EFFECTS OF 2-CHLORODEOXYADENOSINE IN ADULTS WITH ACUTE MYELOID-LEUKEMIA", Blood, 84(10), 1994, pp. 3429-3434
65. FRANKEL SR; EARDLEY A; HELLER G; BERMAN E; MILLER WH; DMITROVSKY E; WARRELL RP
    ALL-TRANS-RETINOIC ACID FOR ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OFTHE NEW-YORK STUDY
    Annals of internal medicine
    
    S.R. Frankel et al., "ALL-TRANS-RETINOIC ACID FOR ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OFTHE NEW-YORK STUDY", Annals of internal medicine, 120(4), 1994, pp. 278-286
66. NUSSBAUM SR; WARRELL RP; RUDE R; GLUSMAN J; BILEZIKIAN JP; STEWART AF; STEPANAVAGE M; SACCO JF; AVERBUCH SD; GERTZ BJ
    DOSE-RESPONSE STUDY OF ALENDRONATE SODIUM FOR THE TREATMENT OF CANCER-ASSOCIATED HYPERCALCEMIA
    Journal of clinical oncology
    
    S.R. Nussbaum et al., "DOSE-RESPONSE STUDY OF ALENDRONATE SODIUM FOR THE TREATMENT OF CANCER-ASSOCIATED HYPERCALCEMIA", Journal of clinical oncology, 11(8), 1993, pp. 1618-1623
67. WARRELL RP; LOVETT D; DILMANIAN FA; SCHNEIDER R; HEELAN RT
    LOW-DOSE GALLIUM NITRATE FOR PREVENTION OF OSTEOLYSIS IN MYELOMA - RESULTS OF A PILOT RANDOMIZED STUDY
    Journal of clinical oncology
    
    R.P. Warrell et al., "LOW-DOSE GALLIUM NITRATE FOR PREVENTION OF OSTEOLYSIS IN MYELOMA - RESULTS OF A PILOT RANDOMIZED STUDY", Journal of clinical oncology, 11(12), 1993, pp. 2443-2450
68. WARRELL RP; CROWN JP
    RECOVERY FROM EXTREME HYPERCALCEMIA
    Lancet
    
    R.P. Warrell e J.P. Crown, "RECOVERY FROM EXTREME HYPERCALCEMIA", Lancet, 342(8867), 1993, pp. 375-375
69. MUINDI JF; STEVENS YW; WARRELL RP; YOUNG CW
    INVITRO DIFFERENTIAL METABOLISM OF MERBARONE BY XANTHINE-OXIDASE AND MICROSOMAL FLAVOENZYMES - THE ROLE OF REACTIVE OXYGEN SPECIES
    Drug metabolism and disposition
    
    J.F. Muindi et al., "INVITRO DIFFERENTIAL METABOLISM OF MERBARONE BY XANTHINE-OXIDASE AND MICROSOMAL FLAVOENZYMES - THE ROLE OF REACTIVE OXYGEN SPECIES", Drug metabolism and disposition, 21(3), 1993, pp. 410-414
70. WARRELL RP; DETHE H; WANG ZY; DEGOS L
    ACUTE PROMYELOCYTIC LEUKEMIA
    The New England journal of medicine
    
    R.P. Warrell et al., "ACUTE PROMYELOCYTIC LEUKEMIA", The New England journal of medicine, 329(3), 1993, pp. 177-189
71. WARRELL RP
    RETINOID RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA - NEW MECHANISMS,STRATEGIES, AND IMPLICATIONS
    Blood
    
    R.P. Warrell, "RETINOID RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA - NEW MECHANISMS,STRATEGIES, AND IMPLICATIONS", Blood, 82(7), 1993, pp. 1949-1953
72. MILLER WH; LEVINE K; DEBLASIO A; FRANKEL SR; DMITROVSKY E; WARRELL RP
    DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIABY A REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION ASSAY FOR THE PML RAR-ALPHA FUSION MESSENGER-RNA
    Blood
    
    W.H. Miller et al., "DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIABY A REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION ASSAY FOR THE PML RAR-ALPHA FUSION MESSENGER-RNA", Blood, 82(6), 1993, pp. 1689-1694
73. VAHDAT L; WARRELL RP
    TREATMENT OF ACUTE MYELOBLASTIC-LEUKEMIA IN ADULTS WITH 2-CHLORO-DEOXYADENOSINE
    Blood
    
    L. Vahdat e R.P. Warrell, "TREATMENT OF ACUTE MYELOBLASTIC-LEUKEMIA IN ADULTS WITH 2-CHLORO-DEOXYADENOSINE", Blood, 82(10), 1993, pp. 10000129-10000129
74. VADHAT L; EARDLEY A; HELLER G; WARRELL RP
    LEUKOCYTOSIS, THE RETINOIC ACID (RA) SYNDROME, AND EARLY MORTALITY INACUTE PROMYELOCYTIC LEUKEMIA (APL) - WHEN IS CHEMOTHERAPY NEEDED DURING REMISSION INDUCTION WITH ALL-TRANS RA
    Blood
    
    L. Vadhat et al., "LEUKOCYTOSIS, THE RETINOIC ACID (RA) SYNDROME, AND EARLY MORTALITY INACUTE PROMYELOCYTIC LEUKEMIA (APL) - WHEN IS CHEMOTHERAPY NEEDED DURING REMISSION INDUCTION WITH ALL-TRANS RA", Blood, 82(10), 1993, pp. 10000192-10000192
75. JURCIC JG; CARON PC; MILLER WH; YAO TJ; MASLAK P; FINN R; LARSON SM; WARRELL RP; SCHEINBERG DA
    I-131-LABELED ANTI-CD33 (I-131-M195) MAY PROLONG DISEASE-FREE SURVIVAL (DFS) IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) AFTER REMISSIONINDUCTION WITH ALL-TRANS-RETINOIC ACID (RA)
    Blood
    
    J.G. Jurcic et al., "I-131-LABELED ANTI-CD33 (I-131-M195) MAY PROLONG DISEASE-FREE SURVIVAL (DFS) IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) AFTER REMISSIONINDUCTION WITH ALL-TRANS-RETINOIC ACID (RA)", Blood, 82(10), 1993, pp. 10000193-10000193
76. XIAO YH; MILLER WH; WARRELL RP; DMITROVSKY E; ZELENETZ AD
    PULSED-FIELD GEL-ELECTROPHORESIS ANALYSIS OF RETINOIC ACID RECEPTOR-ALPHA AND PROMYELOCYTIC LEUKEMIA REARRANGEMENTS - DETECTION OF THE T(1517) TRANSLOCATION IN THE DIAGNOSIS OF ACUTE PROMYELOCYTIC LEUKEMIA
    The American journal of pathology
    
    Y.H. Xiao et al., "PULSED-FIELD GEL-ELECTROPHORESIS ANALYSIS OF RETINOIC ACID RECEPTOR-ALPHA AND PROMYELOCYTIC LEUKEMIA REARRANGEMENTS - DETECTION OF THE T(1517) TRANSLOCATION IN THE DIAGNOSIS OF ACUTE PROMYELOCYTIC LEUKEMIA", The American journal of pathology, 143(5), 1993, pp. 1301-1311
77. RIGAS JR; FRANCIS PA; MUINDI JRF; KRIS MG; HUSELTON C; DEGRAZIA F; ORAZEM JP; YOUNG CW; WARRELL RP
    CONSTITUTIVE VARIABILITY IN THE PHARMACOKINETICS OF THE NATURAL RETINOID, ALL-TRANS-RETINOIC ACID, AND ITS MODULATION BY KETOCONAZOLE
    Journal of the National Cancer Institute
    
    J.R. Rigas et al., "CONSTITUTIVE VARIABILITY IN THE PHARMACOKINETICS OF THE NATURAL RETINOID, ALL-TRANS-RETINOIC ACID, AND ITS MODULATION BY KETOCONAZOLE", Journal of the National Cancer Institute, 85(23), 1993, pp. 1921-1926
78. MILLER WH; KAKIZUKA A; FRANKEL SR; WARRELL RP; DEBLASIO A; LEVINE K; EVANS RM; DMITROVSKY E
    REVERSE TRANSCRIPTION POLYMERASE CHAIN-REACTION FOR THE REARRANGED RETINOIC ACID RECEPTOR-ALPHA CLARIFIES DIAGNOSIS AND DETECTS MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA
    Proceedings of the National Academy of Sciences of the United Statesof America
    
    W.H. Miller et al., "REVERSE TRANSCRIPTION POLYMERASE CHAIN-REACTION FOR THE REARRANGED RETINOIC ACID RECEPTOR-ALPHA CLARIFIES DIAGNOSIS AND DETECTS MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA", Proceedings of the National Academy of Sciences of the United Statesof America, 89(7), 1992, pp. 2694-2698